DexCom, Inc. (NASDAQ:DXCM – Get Rating) SVP Matthew Vincent Dolan sold 2,303 shares of the firm’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $115.00, for a total value of $264,845.00. Following the transaction, the senior vice president now directly owns 33,569 shares in the company, valued at approximately $3,860,435. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Matthew Vincent Dolan also recently made the following trade(s):
- On Monday, March 13th, Matthew Vincent Dolan sold 6,229 shares of DexCom stock. The stock was sold at an average price of $106.27, for a total value of $661,955.83.
- On Monday, March 6th, Matthew Vincent Dolan sold 226 shares of DexCom stock. The stock was sold at an average price of $114.40, for a total value of $25,854.40.
DexCom Price Performance
Shares of DXCM stock traded down $0.63 during midday trading on Friday, reaching $113.93. 2,623,893 shares of the company traded hands, compared to its average volume of 2,657,800. The firm’s 50 day simple moving average is $111.05 and its two-hundred day simple moving average is $106.34. DexCom, Inc. has a 1-year low of $66.89 and a 1-year high of $134.76. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.99 and a quick ratio of 1.83. The firm has a market cap of $44.02 billion, a PE ratio of 140.22, a price-to-earnings-growth ratio of 2.75 and a beta of 1.10.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on DXCM shares. Citigroup increased their target price on shares of DexCom from $117.00 to $146.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Stifel Nicolaus increased their target price on shares of DexCom from $120.00 to $130.00 in a research note on Tuesday, December 20th. Cowen increased their target price on shares of DexCom from $114.00 to $125.00 and gave the stock an “outperform” rating in a research note on Friday, February 10th. StockNews.com started coverage on shares of DexCom in a research note on Thursday. They set a “hold” rating for the company. Finally, Morgan Stanley increased their target price on shares of DexCom from $117.00 to $131.00 and gave the stock an “equal weight” rating in a research note on Friday, January 6th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $123.00.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Sound Income Strategies LLC increased its stake in shares of DexCom by 300.0% during the 3rd quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock worth $26,000 after purchasing an additional 240 shares in the last quarter. Ronald Blue Trust Inc. increased its stake in shares of DexCom by 860.5% during the 3rd quarter. Ronald Blue Trust Inc. now owns 365 shares of the medical device company’s stock worth $27,000 after purchasing an additional 327 shares in the last quarter. James Investment Research Inc. purchased a new position in shares of DexCom during the 4th quarter worth approximately $27,000. Private Trust Co. NA purchased a new position in shares of DexCom during the 2nd quarter worth approximately $29,000. Finally, Close Asset Management Ltd grew its stake in DexCom by 200.0% in the 4th quarter. Close Asset Management Ltd now owns 264 shares of the medical device company’s stock worth $30,000 after acquiring an additional 176 shares during the period. 94.01% of the stock is owned by hedge funds and other institutional investors.
DexCom Company Profile
DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.